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Background: Members of the ALDH1 protein family, known as retinal dehydrogenases (RALDH), produce retinoic
acid (RA), a metabolite of vitamin A, and may also oxidize other lipid aldehydes. Of three related ALDH1 genes,
ALDH1A1 is most highly expressed in liver. ALDH1A1 is also rapidly gaining importance as a stem cell marker.
We hypothesized that ALDH1A1 may have a broad cellular distribution in the liver, and that its expression may be
regulated by RA and perturbed by inflammation.
Methods: Studies were conducted in vitamin A-deficient and –adequate rats that were further treated with
all-trans-RA or lipopolysaccharide (LPS) to induce a state of moderate inflammation. RALDH1A1 expression was
determined by quantitative PCR and RALDH1, as well as marker gene expression, was determined by
immunocytochemical methods.
Results: Inflammation reduced ALDH1A1 mRNA in whole liver regardless of the level of vitamin A in the diet
(P < 0.05), while treatment with RA reduced ALDH1A1 expression only in chow-fed rats. ALDH1A1 protein exhibited
diffuse staining in hepatocytes, with greater intensity in the periportal region including surrounding bile ducts. Six h
after administration of LPS, portal region macrophages were more numerous and some of these cells contained
ALDH1A1. Vimentin, which was used as a marker for stellate cells and fibroblasts, was increased by LPS, P = 0.011 vs.
without LPS, in both ED1 (CD68)-positive macrophages and fibroblastic stellate-like cells in the parenchyma as well as
portal regions. Alpha-smooth muscle actin staining was intense around blood vessels, but did not change after LPS or
RA, nor overlap with staining for vimentin.
Conclusions: Acute inflammation rapidly downregulates ALDH1A1 expression in whole liver while increasing its
expression in periportal macrophages. Changes in ALDH1A1 expression appear to be part of the early acute-phase
inflammatory response, which has been shown to alter the expression of other retinoid homeostatic genes. In addition,
the rapid strong response of vimentin expression after treatment with LPS suggests that increased vimentin may be a
useful marker of early hepatic inflammation.Background
The ALDH1 gene and protein family is comprised of 3 iso-
forms, ALDH1A1 (Aldh1a1 in mouse), ALDH1A2, and
ALDH1A3 [1-3], each of which is involved in the irrevers-
ible oxidative metabolism of the vitamin A metabolite
retinal to form all-trans-retinoic acid (RA). Due to the* Correspondence: acr6@psu.edu
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unless otherwise stated.activity of these enzymes in retinoid metabolism the
ALDH1A1, ALDH1A2, and ALDH1A3 genes and pro-
teins are alternatively known as RALDH1, RALDH2,
and RALDH3, respectively. Each gene is expressed in a
different tissue-specific pattern in embryonic and adult
tissues [4-6]. Besides their role in RA production, the
ALDH1 enzymes are known to be capable of metabol-
izing several aldehydes including acetaldehyde and
lipoxygenase-produced reactive oxygen species [1,3,4].
Various functions have been proposed for ALDH1, in-
cluding as a regulator of hepatic gluconeogenesis [7].
Recently, ALDH1A1 has gained attention as a putativeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Thus, a further understanding its regulation in vivo is
crucial. ALDH1A1 has been studied most extensively in
the eye [10], but it is known to be expressed more broadly
[1-3], including in the fetal and adult liver [3,5,11], lung,
kidney, spleen, stomach, intestine, brain, heart, muscle
and thymus [3,12-15], and certain cells of the immune
system [3-5,12-14,16,17].
Retinal sits at a pivotal juncture in the retinol metabolic
pathway, where it can either be reduced to form retinol,
which, in turn, can be esterified to form retinyl esters for
storage, or it can be oxidized in an irreversible manner to
form RA [4,18], an important regulator of gene transcrip-
tion through its binding to nuclear RA receptors [18,19].
Previous studies conducted in mice have shown that RA
regulates Aldh1a1 expression through an RAR-dependent
feedback inhibition mechanism [3,19,20]. In previous
studies, RALDH1 mRNA was lower in both liver and
kidney of rats fed vitamin A-deficient diet compared to
vitamin A-adequate rats, while the administration of
RA to vitamin A-deficient rats for 4 days restored
RALDH1 mRNA levels in kidney but not in liver [6]. In
contrast, treatment of vitamin A-deficient rats with either
RA or retinol suppressed the expression of the RALDH
gene in the stomach and intestine [14]. ALDH1A1 mRNA
expression was also suppressed in the liver of mice lacking
the arylhydrocarbon receptor, Ahr, which was attributed
to an increased concentration of RA present in the liver
of those mice [20]. The proximal region of the human
ALDH1A1 promoter contains a functional DNA re-
sponse element for RARα that was shown to cooperate
with C/EBPβ in the expression of the ALDH1A1 gene in
liver cells [20]. RA suppressed the expression of C/EBPβ
and, as a result, reduced the activity of the promoter
[20]. However, although the proximal region of the rat
ALDH1A1 promoter has been shown to be essential for
expression it apparently is not responsive to RA in
kidney cells [21]. Thus, ALDH1A1 gene expression may
be regulated differently in various tissues, or in different
cells within tissues.
The regulation and localization of ALDH1A1 in the
liver under physiological and pathophysiological condi-
tions is still not well understood. ALDH1A1 has been re-
ported to be present in rat hepatic stellate cells (HSC) [22]
and hepatocytes [11]. In the current study, we hypothe-
sized that the expression of ALDH1A1 may be regulated
not only by RA but also during inflammation, which has
not been studied previously. Other retinoid homeostatic
genes including retinol-binding protein (RBP4), lecithin:
retinol acyltransferase (LRAT), the short-chain dehydro-
genase/reductase known as retSDR1/DHRS3 [4], and the
cytochrome P450s CYP26A1 and CYP26B1 have all been
shown to be significantly perturbed during inflammation
[23-29]. In the present study we have investigated whetherdifferences in vitamin A status and acute inflammation
alter the hepatic expression of ALDH1A1, and character-
ized the localization of ALDH1A1 under these physio-
logical and pathophysiological conditions.
Methods
Materials
All-trans-RA was purchased from Sigma-Aldrich, St. Louis,
MO. LPS purified from Pseudomonas aeruginosa was
obtained from List Biological Laboratories (Campbell,
CA). Vitamin A-deficient and adequate purified diets
[30] (D13110G and D02080202, respectively) were pur-
chased from Research Diets, Inc., New Brunswick, NJ.
The stock chow diet was Purina Laboratory Rodent Diet
5001.
Alkaline phosphatase-conjugated anti-DIG antibody
and nitro blue tetrazolium chloride and 5-bromo-4-
chloro-3-indolyl-phosphate, toluidine-salt (NBT/BCIP) was
purchased from Roche (Indianapolis, IN). VECTASTAIN
alkaline phosphatase universal ABC kit AK-5200, VECTAS-
TAIN® Elite ABC kit and VECTOR® red were purchased
from Vector Laboratories, Inc. (Burlingame, CA). Rabbit
monoclonal antibody to ALDH1A1 (ab52492) and rabbit
polyclonal antibody to alpha-smooth muscle (α-SMA,
ab5694) were purchased from Abcam Inc. (Cambridge,
MA). Mouse monoclonal anti-vimentin antibody was
from eBioscience (San Diego, CA) and mouse monoclonal
anti-rat CD68 antibody (ED1) from AbD Serotec (Oxford,
UK). Tyramide Signal Amplification (TSA)-Plus Fluores-
cence Palette System® was purchased from PerkinElmer
Life and Analytical Sciences (Boston, MA).
Animals, diets and treatment design
Approval for the use of animals was obtained from the
Institutional Animal Use and Care Committee of Penn-
sylvania State University. Studies were performed either
with rats fed a chow diet or a casein-based purified diet
that was either vitamin A-adequate (VAA) or vitamin A-
deficient (VAD), as described previously [30]. VAA and
VAD rats were generated by feeding female Sprague–
Dawley rats (Charles River Laboratories, Boston, MA)
VAD AIN-93G diet during the lactation period. From
weaning to the time of treatment at 8 weeks of age, the
offspring were fed either the same diet (VAD group) or
switched to the VAA diet containing 4 mg retinol/kg
(VAA group). Rats were housed in groups of 2–3 rats of
the same sex in a room maintained at 22°C with a 12–12
hour dark–light cycle, with free access to food and
water. At 8 weeks of age the rats were divided in four
groups of n = 4-5/group, with sexes distributed among
all 4 groups, and given one of the following treatments:
canola oil orally and saline i.p. (placebo control); RA,
1 μg/g body weight (BW) in canola oil given orally; LPS,
50 μg/100 g BW in PBS injected i.p. [24,27,29] or both
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ively. Six hours later, rats were euthanized using carbon
dioxide asphyxiation. Portions of liver were frozen in li-
quid nitrogen while a portion from the center of the left
lobe was placed in molds in Tissue-Tek® O.C.T. (Sakura
Finetek, Tefface, CA) on dry ice. Another portion from
the same region was fixed in 4% phosphate-buffered for-
malin (Fisher Scientific, Waltham, MA). Vitamin A status
was determined by measuring plasma retinol concentra-
tion using an HPLC method previously reported [31].
Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted from liver tissue using methods
previously described [29] using TRIzol reagent (Life Tech-
nologies, Carlsbad, CA). cDNA was synthesized using M-
MLV reverse transcriptase (Promega Co., Madison, WI)
and qRT-PCR analysis was performed using 2× iQ™ SYBR®
Green supermix PCR Master Mix (BioRad, Hercules, CA).
Primers were rat ALDH1A1 (NM_022407 or BC061526):
5′-AATCAAGGAAGCTGCAGGAA-3′, 5′-CACCCAGT
TCTCGTCCATTT-3′. Rat Vimentin (NM_031140.1):
5′-AATTGCAGGAGCTGAATGAC-3′, 5′-AATGACT
GCAGGGTGCTCTC-3′. Primers were tested by agarose
gel electrophoresis following RT-PCR reaction to assure
the expected transcript sizes. The ratio of mRNA-to-
ribosomal 18S RNA was calculated, with the average
value of the control group set to 1.0 prior to conducting
statistical analysis.
In situ hybridization
The localization of rat ALDH1A1 mRNA was assessed by
in situ hybridization (ISH). A RNA probe for ALDH1A1
was prepared using methods described elsewhere [32].
cDNA was converted with primer pairs 5′-AGCCAAAC
CAGCAATGTCTT-3′ and 5′-TTCACAACACCTGGGA
AACA-3′ (1925 bp). A sense probe was used for the nega-
tive control. Briefly, frozen liver section, 6 μm in thickness,
were soaked in ice-cold acetone, fixed with 4% parafor-
maldehyde (Sigma-Aldrich)/PBS for 15 min on ice, then
were incubated in 0.1 M triethanolamine (Sigma-Aldrich)
buffer for 5 min, after which 0.5% acetic anhydride
(Sigma-Aldrich) was added and incubated for 10 min.
Prehybridization was performed with 50% formamide
(Sigma-Aldrich) /1X SSC at 60°C for 10 min. After step-
wise dehydration with serial dilution of ethanol (50, 70,
and 100%) the sections were incubated with the probe
in hybridization buffer overnight at 42°C. Finally, sec-
tions were washed, blocked, and incubated with alka-
line phosphatase-conjugated anti-DIG antibody, and
then developed with the substrate NBT/BCIP overnight.
To suppress endogenous phosphatase activity and reduce
background staining, 0.24 mg/mL of levamisole (Sigma-
Aldrich), which was applied with the NBT/BCIP solution.
Counterstaining was performed with methyl green dye.Immunohistochemistry (IHC). IHC was performed to
detect ALDH1A1 protein expression in the liver, using
5-μm thick sections of formalin fixed and paraffin
embedded liver sections. Briefly, paraffin was removed
and antigen retrieval was performed using citrate buffer
(10 mM citric acid, 0.05% Tween 20, pH 6.0) heated up
from 95° to 100°C. Sections were soaked in heated citrate-
buffer and incubated for 30 min, followed by cooling
down for 20 min at room temperature. After rinsing with
PBS for 5 min, the sections were stained with the VEC-
TASTAIN® alkaline phosphatase universal ABC kit AK-
5200 following the manufacturer’s instructions. A 1:100
dilution of rabbit monoclonal antibody to ALDH1A1 was
used for the primary antibody. Blocking buffer without
primary antibody was used for a negative control. NBT/
BCIP substrate was applied for 30 min. To block endogen-
ous alkaline phosphatase activity, 0.24 mg/mL of levami-
sole was applied with the NBT/BCIP solution.
IHC was also used to determine the expressions of ED1,
a rat macrophage marker [33], vimentin, a stellate cell/
fibroblast marker [34,35], and α-smooth muscle actin
(α − SMA), a marker of activated fibroblasts [36]. The
procedures used were similar to those described above
except that for ED1 we add a step to quench endogenous
peroxidase with 0.3% H2O2/PBS for 10 min, and used
VECTASTAIN Elite ABC kit with 3,3-diaminobenzidine
as substrate. For vimentin and αSMA, we used VECTOR
red instead of NBT/BCIP as the substrate, following the
protocol of the manufacturer. Vimentin staining area was
quantified using ilastik v0.5.12 for signal classification [37]
and NIH ImageJ software (http://rsb.info.nih.gov/ij/) for
quantification of signal areas. Each section was coded to
remove treatment identity and the area of the image occu-
pied by tissue (excluding large blood vessels considered as
non-tissue) was determined for each slide, and the area of
vimentin-positive staining was determined for the tissue
area. Data were calculated for vimentin-stained sections
from livers of 9 rats that were not treated with LPS and 8
rats treated with LPS for 6 h. The results were compared
by t-test as described below.
Dual fluorescence in situ hybridization and
immunohistochemistry
Liver frozen sections 8-μm in thickness were used to
perform ISH followed by IHC as described above. The
Tyramide Signal Amplification (TSA)-Plus Fluorescence
Palette System® was used instead of NBT/BCIP for
development. Quenching of endogenous peroxidase was
performed as described in the protocol of the TSA-Plus
Fluorescence system before the blocking step. The anti-
gen retrieval step was performed by incubation in 20 μg/
ml of proteinase K in Tris-EDTA buffer (pH 8.0) for
10 min at 37°C. Blocking buffer was used as described in
the protocol of TSA-Plus Fluorescence system.
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Results are shown as mean ± SEM. Student’s t-test, or
one- or two-way ANOVA was performed with Fisher’s
or Holm-Sidak posthoc tests using PRISM (GraphPad,
San Diego, CA) or SigmaPlot (SYSTAT Software, Inc.,
San Jose, CA). When variances were unequal the data
were log10 transformed before analysis. P ≤0.05 was
considered statistically significant.
Results
ALDH1A1 mRNA expression is reduced by LPS regardless
of vitamin A status
We first confirmed that the major isoform of RALDH
expressed in rat liver is ALDH1A1, similar to reports for
human liver [13]. Based on cycle threshold values, the
relative expression of ALDH1A1 in the liver of chow-fed
rats was 100–1000 times greater than ALDH1A2 and 30
times greater than ALDH1A3. We therefore focused on
ALDH1A1 in these studies.
In rats fed a normal chow diet, ALDH1A1 mRNA
levels were reduced moderately after treatment with RA
(P < 0.05), while treatment with low-dose LPS [24,27,29]
for 6 h, as a model for the early stages of mild acute in-
flammation, resulted in a greater reduction of expression
(P < 0.05 versus control and RA groups) (Figure 1A), and
shown by gel electrophoresis of PCR products in Figure 1B.
In rats fed VAA or VAD purified diets, vitamin A status at
the end of the study differed significantly as shown by
plasma retinol concentration (1.0 μM in VAA vs. 0.2 μM
in VAD rats, respectively, P < 0.0001). However, there were
no differences in body weight, indicating that the vitamin
A deficiency was moderate. There were no differences in
plasma retinol due to RA or LPS treatment, which may
have been due to the short treatment. The relative abun-
dance of ALDH1A1 mRNA did not differ after RA alone.
It was reduced marginally but not statistically by LPS
treatment in VAA rats (P < 0.05), and differed significantly
in VAA rats treated with LPS + RA, P < 0.05 (Figure 1B).
Therefore, both in rats fed chow diet (Figure 1A) and
those fed purified diet (Figure 1C), ALDH1A1 mRNA was
rapidly and significantly reduced after treatment either
with LPS alone (Figure 1A) or with LPS in the presence of
RA (Figure 1C).
Location of ALDH1A1 mRNA by ISH
The localization of ALDH1A1 mRNA in the liver was
determined by in situ hybridization (Figure 2). In VAA
liver (shown) and VAD liver (similar and therefore not
shown) ALDH1A1 mRNA signals were observed through-
out the liver with relatively light staining in hepatocytes,
which was somewhat weaker surrounding the central vein.
Staining using the sense strand control showed only a
light and relatively even distribution. Hepatocytes from
vehicle-treated rats expressed ALDH1A1 mRNA in oraround nuclei, while this was hardly observed in the RA-
or LPS-treated groups. ALDH1A1 staining was more in-
tense around vessels, especially in the periportal region,
including around bile ducts, as shown in the vehicle-
treated section. The sense control showed essentially no
discrete staining. Conversely, there was no specific stain-
ing around blood vessels in the portal tracts. These results
indicate that several types of liver cells express ALDH1A1
mRNA, including vascular epi- or endothelial cells and
nonparenchymal cells within the portal tract. Sections
from rats treated with LPS, both with and without RA, ap-
peared to be more lightly stained. However, the distribu-
tion of ALDH1A1-positive cells was similar.
Localization of ALDH1A1 protein with the rat
macrophage marker ED1 during acute inflammation
Treatment with LPS is well known to induce activation
of macrophages [38,39]. To examine whether macrophages
express ALDH1A1, we next conducted dual fluorescence
imaging for ALDH1A1 mRNA and ED1 protein, a marker
for rat macrophages. Costaining with a fluorescently-
stained antisense RNA probe to ALDH1A1 and antibodies
to ED1 in rats fed VAD diet (Figure 3), identified some of
the cells producing ALDH1A1 (green signals) as being lo-
cated in the periportal area where ED1 stained macro-
phages (red signals) were also located. Typical images are
illustrated. Although not all macrophages were positive
for ALDH1A1, there was still a noticeable increase in
ALDH1A1 staining (green) in the LPS and RA + LPS-
treated groups compared to the control and RA only
groups. Some of the ALDH1A1 signals overlapped with
ED1 signals (yellow merged signals, row 3, in the LPS and
LPS + RA groups). DAPI staining was used to visualize the
nuclei in these sections (row 4). Thus, despite a lower over-
all expression of ALDH1A1 in the tissue as determined
by qRT-PCR (Figure 1), the expression of ALDH1A1 in
macrophages was increased by treatment with LPS. The
co-localization of ALDH1A1 and ED1 is further illus-
trated for LPS-treated liver at the bottom of Figure 3,
where higher power images are shown. There was a
nearly complete overlap of ALDH1A1 and ED1 signals.
Together, these results suggest that acute LPS-induced
inflammation intensifies ALDH1A1 expression in peri-
portal macrophages.
Localization of ALDH1A1 protein with the rat stellate
cell/fibroblast marker vimentin
Additional localization studies with dual IHC using anti-
ALDH1A1 and anti-ED1 (Figure 4), or anti-ALDH1A1
and anti-vimentin (Figure 5) were performed on the sec-
tions of liver from VAA and VAD rats. We did not ob-
serve a noticeable overall decrease in ALDH1A1 protein
staining, which may have been due to the short time,

































































































































Figure 1 (See legend on next page.)
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Figure 1 ALDH1A1 mRNA relative expression levels in 8-wk old rats fed chow diet (A and B) and in VAA and VAD rats (C). Total RNA
was extracted from the liver samples of individual rats and quantified by real time PCR with SYBR Green for ALDH1A1 and 18S ribosomal RNA
(rRNA) (A and C). Upon completion, the PCR products from individual samples in Figure 1A were pooled in each group and subjected to ethidium
bromide agarose gel electrophoresis, with DNA molecular weight markers (MWM) (B). Values in A and C were individually normalized to 18S RNA and
are expressed as the mean ± SEM of n = 4-6/group. Groups not sharing a common letter were significantly different, P <0.05 (a > b > c).
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was present in the parenchyma and in the portal areas, es-
pecially surrounding bile ducts where intense staining was
observed. ED1 staining (pink signals, Figure 4) was scat-
tered throughout the liver, with more ED1 positive cells
both within the portal areas, consistent with Figure 3, and
in the nearby parenchyma of LPS-treated VAA and VAD
rats. Again, the cells lining bile ducts, but not blood ves-
sels, were stained for ALDH1A1 (seen in several images
and marked with black and white arrows, respectively, in
Figure 4 panel d). The negative staining control (panel i)
was completely clean.
ALDH1A1 protein was also compared with vimentin
(Figure 5), used to mark fibroblasts and stellate cells. Re-
sults were similar in both VAA and VAD rats and only re-
sults for VAA rats are illustrated. In vehicle-treated VAA




Sense control (x200) 
Figure 2 ALDH1A1 mRNA expression and localization by in situ
hybridization. Livers of VAA rats were used to detect rat ALDH1A1
mRNA expression (purple color). Green signals show nuclei counter
stained by methyl green dye. Hepatocytes are notable by their large,
round, methyl green-stained nuclei. Staining for ALDH1A1 mRNA
was present throughout the parenchyma but was most intense
around the portal tracts, including surrounding bile ducts (arrow,
vehicle-treated liver). A sense RNA probe control is also illustrated.
Magnification: × 200. Results for VAD liver were similar and therefore
are not shown.hepatic portal areas. Some vimentin staining (pink) was
also observed around blood vessels from which ALDH1A1
was absent. Vimentin staining was stronger in the portal
area and sinusoids of the parenchyma in LPS-treated rats
(Figure 5b). Images shown in Figure 5a and b were proc-
essed so that only the signals for vimentin are shown in
black (Figure 5c, d). These images show that vimentin oc-
cupied a greater area in the LPS-treated liver and that
vimentin signals were scattered throughout the paren-
chyma in small irregularly shaped cells, while the hepato-
cytes that stained positively for ALDH1A1 were relatively
free of vimentin. RA-treated rats did not show an appre-
ciable change in vimentin staining (Figure 5c). The staining
pattern was similar in RA + LPS-treated rats (Figure 5f)
compared to LPS treatment alone (Figure 5b), suggesting
that LPS-induced inflammation rather than treatment with
RA is mainly responsible for the increase in vimentin
protein expression. Vimentin staining was quantified
(see Methods) for identically processed liver sections
from rats that did not receive LPS (n = 9) compared to
rats that had received LPS 6 h before tissue collection
(n = 8), regardless of diet or RA treatment. As shown
in Figure 5g, vimentin staining occupied a significantly
higher percentage of tissue area in the LPS treated group,
P = 0.011.
Lack of colocalization of vimentin and α-smooth muscle
actin (α-SMA) in acute liver inflammation
α-SMA is considered a marker of activated HSC as well
as of myocytes. We compared the distributions of staining
for ED1, the intermediate filament protein vimentin, and
α-SMA after RA, LPS and RA + LPS treatment (Figure 6).
Consistent with Figure 3, ED1 staining was more intense
after LPS treatment (Figure 6c and d compared to 6a and
b). However the change in vimentin staining was more
dramatic, shown by a greater number of more intensely
stained star- or fibroblastic-shaped cells that were dis-
persed among hepatocytes, and was most evident in
the liver parenchyma of LPS and RA + LPS-treated rats
(Figure 6g and h compared to 6e and f ). Vimentin-
positive cells were also present in the subendothelial
mesenchymal tissue around vessels (white arrow in
Figure 6g). Vimentin-positive cells were also scattered
in the subepithelial mesenchymal tissue of the portal
areas (most notable in Figure 6g). On the other hand,
α-SMA staining was present only in the smooth muscle
cells of vessel walls and not in the underlying connective










VAS, LPS-treated liver: 
RALDH1 ED1 RALDH1 
ED1 merged (no DAPI) 
Figure 3 Dual fluorescence images of ALDH1A1 mRNA with ED1 co-staining for the detection of macrophages. Dual fluorescence ISH
and IHC was performed using rat ALDH1A1 antisense probe and ED1 antibody, a rat macrophage marker, respectively, without and with DAPI
staining of nuclei, on sections of VAD rat liver. ED1 was detected in the periportal area. ALDH1A1 staining (green) is increased after treatment
with LPS. Some of the cells expressing ALDH1A1 showed overlapping staining with ED1 (red). Yellow; merged signals from ALDH1A1 and ED1;
purple, merged signals from ED1 and DAPI nuclear stain. Magnification: x100. The co-localization of ALDH1A1 and ED1 is further illustrated for
LPS-treated VAS liver at the bottom of Figure 3, where higher power images are shown (magnification: x200).
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sity did not differ appreciably among treatment groups
(Figure 6i, j, k, l). Fibroblasts did not stain for α-SMA in
our study.
The increase in vimentin protein observed by histology
in Figure 5 was accompanied by a small increase in vime-
tin mRNA in total liver tissue (Figure 7). Regardless of the
treatment group, vimentin mRNA was higher in the liver
of VAD rats than VAA rats (diet effect, P < 0.01). Average
values for vimentin mRNA after LPS treatment were
higher in both VAD and VAA groups, consistent with the
protein staining results shown in Figure 5g, although this
was marginally significant (P = 0.062) only in the VAA
group.
Discussion
The exact role and tissue distribution of ALDH1A1 is still
unclear, and the effect of inflammation on ALDH1A1 has
not been investigated previously. ALDH1A1 has become
of increasing interest recently due to its strong association
with stem cells [40-42] and as a prognostic cancer marker[43]. However, little is known of its tissue distribution or
cellular distribution within tissues under different physio-
logical conditions. In the present study we focused on
ALDH1A1 in the liver because it is a major organ of retin-
oid uptake, storage, metabolism and excretion. We ini-
tially observed that ALDH1A1 mRNA is downregulated
in the liver of normal, chow-fed rats within a short time,
6 h, after treatment with LPS (Figure 1A), under condi-
tions that have been shown to induce a state of moderate
inflammation, characterized by a slight rise in body
temperature and lethargy, but from which animals fully
recover [24]. Previously, LPS-induced acute inflamma-
tion has been shown to modulate the expression of
several other retinoid homeostatic genes, notably, the
short-chain dehydrogenase-reductase retSDR1/DHRS3,
which converts retinal to retinol [28], LRAT, which es-
terifies retinol [28], and the cytochrome P450 enzymes
CYP26A1 and CYP26B1 [29], which oxidizes excess RA
[27], all of which were reduced in the liver of LPS-treated
rats within 3–6 h after LPS administration [28,29]. It is















Figure 4 Co-localization of ALDH1A1 protein expression and
rat macrophage marker ED1 in liver from VAA and VAD rats.
Dual IHC with anti-ALDH1A1 antibody and anti-ED1 antibody was
performed followed by methyl green counterstaining for detection
of nuclei. Anti-ALDH1A1 staining (purple) showed a broad distribution,
which was intense around portal regions and bile ducts, while cells
staining for ED1 (pink-red) was more generally scattered in the
parenchyma and in portal areas after treatment with LPS (Figure 4 e


















Figure 5 Co-localization of ALDH1A1 protein expression and
stellate cell/fibroblast marker, vimentin in liver from VAA rats.
Results for VAD rats were similar and therefore are not shown. Dual
IHC with anti-ALDH1A1 antibody and anti-vimentin antibody was
performed followed by methyl green counterstaining for detection
of nuclei. Staining controls for vimentin were similar to those shown
for ED1 in Figure 4i. Panels c and d show false-color images after
ilastik® processing (see Methods) so that only pink (vimentin) signals
are visible as black. Arrows illustrate some of the cells that co-stained
with purple (ALDH1A1) and vimentin signals (Figure 5a-f). Figure 5e
illustrates the intense ALDH1A1 staining around bile duct structures
(black arrow) and its absence around the arterial smooth muscle region
(white arrow), which is also apparent in other sections. Magnification x 400.
Figure 5g shows the tissue area occupied by vimentin staining,
analyzed by ilastik®, which was significantly higher in the liver of
rats treated with LPS (n = 8 animals) compared to those not treated
with LPS (n = 9 animals, P = 0.011).
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with exogenous RA would result in a down-regulation
of ALDH1A1 expression as a feedback system that might
effect the gene’s expression [44], while, conversely, animals
fed VAD diet and having limited reserves of vitamin A in
tissues may have elevated ALDH1A1 expression to com-
pensation for low substrate availability. However, in our
study neither a dietary deficiency of vitamin A nor direct
administration of RA resulted in a marked change in
ALDH1A1 mRNA expression. This result contrasts with
an earlier report of reduced ALDH1A1/RALDH1 in the
liver of vitamin A-deficient rats, which was not, however,
corrected by treatment with RA [6]. Presently, we do not
have an explanation for these differences between studies.
Inflammation was not studied previously and, in ourstudy, inflammation was a stronger regulator of ALDH1A1
expression than was retinoid status. The physiological role
of ALDH1A1 remains uncertain, and the enzyme may
metabolize a variety of aldehyde substrates [1,3,4,9]. Our
results suggest that their metabolism could be altered in
states of inflammation through a reduction in ALDH1A1
expression.
Our study revealed new information on the regional
distribution and types of cells that are positive for expres-
sion of ALDH1A1. In the parenchymal region, hepatocytes
expressed ALDH1A1 and nearly all hepatocytes showed
pale to relatively intense cytoplasmic staining. However
the most intense staining (Figures 2 and 4) was located in


















Figure 6 Detection of macrophages (a-d), vimentin (e-h), and
α-SMA (i-l) by IHC in liver of VAD rats. ED1 staining (brown)
detected macrophages; vimentin (red) HSC/fibroblasts, and α-SMA
(purple) cells containing smooth-muscle fibers. Nuclei were detected
with methyl green dye. Numerous vimentin-positive star-shaped
cells are present scattered in the parenchymal after treatment with
LPS (panel g, black arrows) or LPS + RA (panel h). The white arrow in
Figure 6g indicates an example of vimentin-positive cells located in






































Diet, P < 0.01
P = 0.062
Figure 7 Relative mRNA expression of vimentin in VAA and
VAD diet rat liver. Vimentin mRNA in VAA (black bars) or VAD
(grey bars) rats, determined by qRT-PCR. Normalized values were
expressed as the mean ± SEM of n = 5 (n = 4 for VAD vehicle)/group,
with the VAA control group set to 1.0. Diet was a significant main
effect, P <0.01, and LPS treatment marginally increased vimentin
mRNA expression, P = 0.062 compared to the VAA vehicle
control group.
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proteins [45]. ALDH1A1 staining was also intense in the
epithelium surrounding the portal venules and bile ducts
(Figure 4a, b). There was little or no staining around
blood vessels. In the portal areas, ALDH1A1-stained
cells were more intense after treatment with LPS. By
fluorescence in situ hybridization, ALDH1A1-positive
cells increased in intensity after LPS or RA + LPS treat-
ment and there was overlap of ALDH1A1 expression
with at least some of the ED1-positive cells in VAD rats.
Thus, changes in the distribution of ALDH1A1 protein
were evident very early after induction of inflammation
in our model.
Previous reports indicated that ALDH1A1 is expressed
in HSC [22] and hepatocytes [11]. HSC are fibroblastic
cells with the capability to synthesize retinyl esters from
retinol and to store large amounts of retinyl esters in
lipid droplets [45-47]. Under normal dietary conditions
and when HSC are in the quiescent state [45] about 80%
of the liver total vitamin A is stored in these cells [46-48].
However, HSC can become activated by inflammatory
stimuli and, during liver injury, undergo a process of acti-
vation in which retinyl ester is lost and RA is produced
[49] and the cells undergo transdifferentiation in which
their stellate-like morphology is lost and the cells become
proliferative, contractile, fibrogenic myofibroblasts [45,49,50].
This process is considered crucial in the etiology of fi-
brotic liver disease [51]. Similarly, other mesenchymal
cells, such as portal fibroblasts, also can become acti-
vated and undergo transdifferentiation into myofibro-
blasts in the portal area, which may be especially
important in biliary fibrosis [45]. Because our studies
were of short duration, we would anticipate that we
could only observe the very initial changes during the
inflammatory, activation process. Thus we can infer that
HSC were beginning to become activated by LPS within
6 h, since vimentin, or vinculin (not shown), a focal ad-
hesion complex protein implicated in the migration of
activated HSC to sites of injury [52], increased in the
liver of LPS-treated rats. At the same time, LPS also re-
sulted in an increase of ALDH1A1 staining in macro-
phages. These results suggest that inflammation may
not only initiate a loss of retinyl esters [49], but also
alter the expression of ALDH1A1, which may have a
further impact on the liver’s ability to regulate retinoid
concentrations. The greater intensity of ALDH1A1 pro-
tein in ED1-positive cells suggests that macrophages,
like dendritic cells in the intestine [12], may turn on
ALDH1A1 expression when they become activated. An
interesting question for the future, which our present
study did not address, is whether the RALDH1A1-
expressing macrophages observed in liver during in-
flammation are resident macrophages (Kupffer cells),
with elevated ALDH1A1 expression, or cells that have
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possible reason for the induction of ALDH1A1 in macro-
phage after LPS treatment could be that ALDH1A1 is
needed to rid cells of substrates other than retinal. As
noted in our introduction, the substrate specificity of
ALDH1A1 is not yet well clarified. Recently, a role was
demonstrated for ALDH1A1 in the clearance of dopa-
mine aldehyde intermediates in neurons [41]. Thus, this
enzyme could play diverse and distinct roles in cell
biology at different sites. Also recently, ALDH1A1 ex-
pression in intestinal CD14+ macrophages in tissue
from patients with Crohn’s disease was linked to increased
RA production and a more inflammatory phenotype [53].
The intense staining of ALDH1A1 observed in the bil-
iary epithelium was unanticipated and is very interesting.
In general, aldehydes are toxic to cells, due to their pro-
pensity to react with proteins and lipids to create non-
metabolizable adducts and thus the ALDH1 family of
enzymes are in general thought to be protective. In the
retina, retinal is known to form potentially toxic prod-
ucts through its reaction with phospholipids and pro-
teins [54]. It is conceivable that ALDH1A1 in the biliary
epithelium plays a role in the elimination of excess alde-
hydes, either retinal and/or other aldehyde compounds,
prior to their excretion, and thus prevents their non-
specific reaction with cells of the biliary tract or the
small intestine prior to their elimination. The carboxylic
acidic products of the ALDH1A1 reaction may also be
amenable to further conversion to aqueous-soluble
products through glucuronidation or sulfation in phase
II metabolic reactions.
Stellate cells are known to be distributed throughout
the liver, display a remarkable array of funtions, and to
display several patterns of intermediate filament protein
expression, including desmin, vimentin, and glial fibril-
lary acidic protein. The display of various patterns of ex-
pression suggests there are subpopulations within this
HSC cell type [51]. Activated fibroblasts are known to
express α-SMA but the neoexpression of α-SMA in
myofibroblasts has been shown to develop slowly, be-
coming observable after several days during the process
of healing of a dermal wound [36]. In our acute studies,
we did not observe parenchymal region staining with
antibodies to α-SMA, whereas α-SMA staining in blood
vessel walls was strong. Stellate cell activation is a more
gradual process with respect to loss of retinyl esters
stored in lipid droplets and the conversion of cell pheno-
type from quiescent HSC to the more myofibroblastic
phenotype associated with collagen production [45,47].
In contrast, we observed a rapid change in the level of
expression of the intermediate filament protein vimentin
(Figure 4B and Figure 5). Vimentin was present in the
deeper layers of mesenchyme around the blood vessels
and, additionally, in cells with the shape and expectedlocation of HSC scattered throughout the parenchyma
(Figure 5). Vimentin has been reported to be expressed
in the same mesenchymal cells as α-SMA in some stud-
ies, for example in esophageal stromal cells [35], while a
study of human fetal liver reported a lack of coincidence
of α-SMA and vimentin [55]. The specific role of vimen-
tin is not yet well clarified. As changes in vimentin pro-
tein were noticeable in the liver of our rats 6 h after
induction of inflammation with LPS, our results suggest
that vimentin may be an excellent marker of early hep-
atic inflammation. Future studies focused on comparing
vimentin, α-SMA and retinoid-related genes during both
acute and prolonged inflammation, and after acute and
chronic liver injury, could help to better understand which
types of cells co-express this marker and under which
types of physiological and pathophysiological states. The
current intense interest in ALDH1A1 as a possible marker
of cancer stem cells [1,8,9] makes understanding its
normal distribution and regulation even more imperative.
Conclusions
ALDH1A1 was regulated in the early stages of the acute-
phase inflammatory response induced by LPS in the intact
liver. However, despite the reduction of ALDH1A1 ex-
pression in whole liver tissue this was countered by an
increased expression in macrophages, suggesting a re-
balancing of its expression and possibly of the role of
ALDH1A1 during inflammation. Potentially, the in-
creased expression of ALDH1A1 in liver macrophages,
which are capable of migration, may help to supply RA
in a mobile form that can be transported by these cells
to sites of tissue repair or regeneration. These studies
add to the understanding of ALDH1A1 expression in
the liver and suggest that further functional studies
should investigate ALDH1A1 under both normal and
inflammatory conditions, with focus on the liver macro-
phage. In addition, our observations on vimentin expres-
sion suggest that this intermediate filament protein may
be very useful as a marker of the early stages of HSC acti-
vation during inflammation.
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